Breakthrough diabetes and weight loss medication may lower a patient’s risks of common cancers closely linked with obesity, a study published on Friday suggests.
Patients taking Ozempic for Type 2 diabetes management developed fewer obesity-related cancers than patients on insulin alone, according to the new study from a team of researchers at Case Western Reserve University School of Medicine.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.